MaaT Pharma
Develops a series of microbiome-based drugs targeting mortality and comorbidities associated with blood cancer treatments.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 Valuation: €0.0 -17.7x EV/EBITDA | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | €37.5m | Post IPO Debt | |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 47 % | 56 % | 44 % | 140 % | 88 % | 118 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (882 %) | (916 %) | (828 %) | (819 %) | (291 %) | (106 %) | (50 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (928 %) | (959 %) | (885 %) | (899 %) | (330 %) | (157 %) | (32 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 941 % | 1012 % | 943 % | 854 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
MaaT Pharma is a late-stage clinical biotechnology company that was founded in 2014 in Lyon, France. The company is focused on developing microbiome-based therapies to improve outcomes for cancer patients.
MaaT Pharma's approach is to use the gut microbiome to modulate the immune system. The company has developed a proprietary platform, called MaaT Microbiome Restoration Biotherapeutics (MMRB), to create standardized, high-diversity microbiome drug candidates. This platform utilizes pooling and co-cultivation technologies to ensure the consistency and quality of its products.
The company's lead product candidate, MaaT013, is in late-stage clinical development for the treatment of acute Graft-versus-Host Disease (aGvHD), a life-threatening complication of allogeneic hematopoietic stem cell transplantation. MaaT Pharma is also developing MaaT033, a second-generation product candidate, for the prevention of complications after allogeneic hematopoietic stem cell transplantation.
MaaT Pharma's business model is focused on the development and commercialization of its microbiome-based therapies. The company generates revenue through a combination of research and development collaborations, licensing agreements, and product sales. MaaT Pharma is publicly traded on the Euronext Paris stock exchange under the ticker symbol MAAT since 2021.
Keywords: microbiome, oncology, immunotherapy, biotechnology, clinical-stage, gut-health, cancer-therapies, graft-versus-host-disease, biotherapeutics, drug-development